β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study

References

• Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification. Ann Hematol. 1999;78:495–506.
   PubMed Web of Science ®Google Scholar
• Murray J. Myeloproliferative disorders. Clin Med. 2005;5:328–332.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Mora B, Maffioli M. New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. Curr Opin Hematol. 2016;23:137–143. doi:10.1097/MOH.0000000000000218.
   PubMed Web of Science ®Google Scholar
• Gumbiner BM. Signal transduction of B-catenin. Curr Opin Cell Biol. 1995;7:634–640.
   PubMed Web of Science ®Google Scholar
• Qiang YW, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005;106:1786–1793.
   PubMed Web of Science ®Google Scholar
• Thakur R, Mishra DP. Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med. 2013;17:449–456.
   PubMed Web of Science ®Google Scholar
• Reya T, Clevers H. Wnt signaling in stem cells and cancer. Nature. 2005;434:843–850.
   PubMed Web of Science ®Google Scholar
• Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science. 1997;275:1790–1792.
   PubMed Web of Science ®Google Scholar
• Rask K, Nilsson A, Brännström M, et al. Wnt-signaling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer. 2003;89:1298–1304.
   PubMed Web of Science ®Google Scholar
• Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol. 2002;71:388–400.
   PubMed Web of Science ®Google Scholar
• Garcia-Bates TM, Lehmann GM, Simpsom-Haidaris PJ, Beknstein SH, Sime PJ, Phipps RP. Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res. 2008;2008:834612.
   PubMedGoogle Scholar
• Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol. 2006;26:5827–5837. doi:10.1128/MCB.00441-06.
   PubMed Web of Science ®Google Scholar
• Gerhold DL, Liu F, Jiang G, et al. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology. 2002;143:2106–2118. doi:10.1210/endo.143.6.8842.
   PubMed Web of Science ®Google Scholar
• Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem. 2004;279:35583–35594. doi:10.1074/jbc.M403143200.
   PubMed Web of Science ®Google Scholar
• Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer. 2002;102:338–342. doi:10.1002/ijc.10719.
   PubMed Web of Science ®Google Scholar
• Bellei B, Pacchiarotti A, Perez M, Faraggiana T. Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Mod Pathol. 2004;17:1275–1281. doi:10.1038/modpathol.3800181.
   PubMed Web of Science ®Google Scholar
• Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature. 2003;421:547–551. doi:10.1038/nature01345.
   PubMed Web of Science ®Google Scholar
• Reya T, Duncan AW, Ailles L, et al. A role for Wnt signaling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–414. doi:10.1038/nature01593.
   PubMed Web of Science ®Google Scholar
• Serinsoz E, Neusch M, Busche G, Wasielewski R, Kreipe H, Bock O. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol. 2004;126:313–319. doi:10.1111/j.1365-2141.2004.05049.x.
   PubMed Web of Science ®Google Scholar
• Johansson B, Billström R, Kristoffersson U, et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia. 1997;11:1207–1213.
   PubMed Web of Science ®Google Scholar
• Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPARγ and are killed by PPARγ agonists. Clin Immunol. 2002;103:22–33. doi:10.1006/clim.2001.5181.
   PubMed Web of Science ®Google Scholar
• Ulivieri C, Baldari CT. The potential of peroxisome proliferator-activated receptorγ(PPARγ) ligands in the treatment of hematological malignancies. Mini Rev Med Chem. 2007;7:877–887.
   PubMed Web of Science ®Google Scholar
• Ray DM, Spinelli SL, O´Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARγ ligands: implications for inflammation, diabetes and cardiovascular disease. Bio Drugs. 2006;20:231–241. doi:10.2165/00063030-200620040-00004.
   Google Scholar
• Wang Y, Porter WW, Suh N, et al. A synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000;14:1550–1556. doi:10.1210/mend.14.10.0545.
   PubMed Web of Science ®Google Scholar
• Botrugno OA, Fayard E, Annicotte JS, et al. Synergy between LRH-1 and beta-catenin induces G1cyclin-mediated cell proliferation. Mol Cell. 2004;15:499–509.
   PubMed Web of Science ®Google Scholar
• Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA. 2002;99:13771–13776. doi:10.1073/pnas.162480299.
   PubMed Web of Science ®Google Scholar
• Lu D, Cottam HB, Corr M, Carson DA. Repression of beta-catenin function in malignant cells by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA. 2005;102:18567–18571.
   PubMed Web of Science ®Google Scholar
• Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem. 2004;279:45020–45027.
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60–70. doi:10.1182/blood-2007-05-091850.
   PubMed Web of Science ®Google Scholar
• Thiele J. Philadelphia chromosome negative chronic myeloproliferative disease. Am J Clin Pathol. 2009;132:261–280. doi:10.1309/AJCPR8GINMBDG9YG.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Verstovek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012;19:4–15.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Marinez-Trillos A. Myelofibrosis: an update on current pharmacotherapy and future directions. Exp Opin Pharmacother. 2013;14:873–884.
   PubMed Web of Science ®Google Scholar
• Briere J, Kiladjian JJ, Peynaud-Debayle E. Megakaryocytes and platelets in myeloproliferative disorders. Baillieres Clin Haematol . 1997;10:65–88.
   PubMedGoogle Scholar
• Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low)mice). Blood. 2002;100:1123–1132.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110:986–993.
   PubMed Web of Science ®Google Scholar